Harpoon Therapeutics, Inc.
HARPDelisted Mar 11, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708493
Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Harpoon Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Harpoon Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lathi Vijay K | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf Ventures III, L.P. | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf Venture Associates III, L.P. | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf Venture Management III, L.L.C. | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf Biopharma Opportunities II, L.P. | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf BPO Management II, L.L.C | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| New Leaf BPO Associates II, L.P. | Director, 10% Owner | 0 | Mar 11, 2024 | 0 |
| Merck Sharp & Dohme LLC | 10% Owner | 1,000Indirect | Mar 11, 2024 | 0 |
| Merck & Co., Inc. | 10% Owner | 1,000Indirect | Mar 11, 2024 | 0 |
| Bailes Joseph S | Director | 0 | Mar 11, 2024 | 0 |
| Silvernail Lauren P | Director | 0 | Mar 11, 2024 | 0 |
| Hunt Ronald | Director, 10% Owner | 0Indirect | Mar 11, 2024 | 0 |
| Myers Scott Dunseth | Director | 0 | Mar 11, 2024 | 0 |
| Eastland Julia Marie | President and CEO | 0 | Mar 11, 2024 | 0 |
| Drachman Jonathan G | Director | 0 | Mar 11, 2024 | 0 |
| Robbins Andrew R | Director | 0 | Mar 11, 2024 | 0 |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | 0 | Mar 11, 2024 | 0 |
| Bucher James B | Chief Legal Officer | – | Mar 11, 2024 | 0 |
| Walker Luke Nathaniel | Chief Medical Officer | 0 | Mar 11, 2024 | 0 |
| Chin Mark | Director | 0 | Mar 11, 2024 | 0 |
| Colowick Alan | Director | 16,456 | Apr 4, 2023 | 0 |
| Viney Joanne L. | Director | 21,028 | Apr 4, 2023 | 0 |
| Erbez Georgia | Chief Financial Officer | 19,215Indirect | Feb 1, 2022 | 0 |
| Sacks Natalie | Chief Medical Officer | – | Feb 1, 2022 | 0 |
| Wesche Holger | Chief Scientific Officer | 52,852 | Feb 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2024 (view filing)3:27 PM ET | Mar 11 | Same day | Merck Sharp & Dohme LLC and 1 other10% Owner | PPurchaseCommon Stock, par value $0.0001 | +21.4M | $23.00 | +$492.1M | New position1.00K after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +1.37M | – | – | +1,501.3%1.46M after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +171.5K | – | – | +76.5%395.8K after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +686.0K | – | – | –686.0K after | Derivative |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +85.8K | – | – | –85.8K after | Derivative |
| Oct 27, 2023 (view filing) | Oct 25 | 2 days | Hunt RonaldDirector, 10% Owner | PPurchase | +1.54M | – | – | New position395.8K after | 2 lots |
| Oct 27, 2023 (view filing) | Oct 25 | 2 days | Hunt RonaldDirector, 10% Owner | PPurchase | +771.8K | – | – | –85.8K after | Derivative2 lots |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Hunt RonaldDirector, 10% Owner | PPurchase8.000% Series A Redeemable Preferred Stock | +10.0K | $1,000.00 | +$10.0M | New position10.0K after | |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Hunt RonaldDirector, 10% Owner | PPurchase | +2.99M | – | – | –2.99M after | Derivative |
| Sep 22, 2021 (view filing) | Sep 22 | Same day | Erbez GeorgiaChief Financial Officer | PPurchase | +10.3K | $8.10 | +$83.4K | +115.5%19.2K after | |
| Aug 12, 2021 (view filing)4:15 PM ET | Jan 11 | 213 daysLate | New Leaf Ventures III, L.P. and 5 others10% Owner | PPurchase | +235.3K | $17.00 | +$4.00M | +34.7%913.9K after | Duplicate filing |
| Aug 12, 2021 (view filing) | Jan 11 | 213 daysLate | Hunt RonaldDirector, 10% Owner | PPurchase | +235.3K | $17.00 | +$4.00M | +34.7%913.9K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Wesche HolgerChief Scientific Officer | SSale | −10.0K | $14.00 | −$140.0K | −15.9%52.9K after |